PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer

• Published in: Oncogene Vol. 34; no. 22; pp. 2897 - 2909
• Main Authors: Lee, K-H, Park, J-W, Sung, H-S, Choi, Y-J, Kim, W H, Lee, H S, Chung, H-J, Shin, H-W, Cho, C-H, Kim, T-Y, Li, S-H, Youn, H-D, Kim, S J, Chun, Y-S
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28-05-2015; Nature Publishing Group
• Subjects: 13/51; 13/95; 38/39; 38/77; 631/67/581; 64/60; 82/1; 82/80; 96/106; Animals; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Cancer; Carcinogenesis; Cell Biology; Cell death; Cell Death - drug effects; Chemotherapy; Chromatin; Colon cancer; Colorectal cancer; Colorectal carcinoma; Cyclin-dependent kinase inhibitor p21; Doxorubicin; Epigenetics; Flowers & plants; Gastric cancer; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Genes, Tumor Suppressor; Genetic aspects; Genetic regulation; Genomes; Genotoxicity; HCT116 Cells; Health aspects; HEK293 Cells; Hep G2 Cells; Homeobox; Homeodomain Proteins - antagonists & inhibitors; Homeodomain Proteins - physiology; Human Genetics; Humans; Informatics; Internal Medicine; MCF-7 Cells; Medicine; Medicine & Public Health; Methyltransferases; Mice; Mice, Nude; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; Oncology; original-article; Oxaliplatin; p53 Protein; Properties; RNA, Small Interfering - pharmacology; Stomach; Temperature effects; Transcription; Tumor Cells, Cultured; Tumor proteins; Tumor suppressor genes; Tumor Suppressor Protein p53 - physiology; Tumors; Xenograft Model Antitumor Assays; Xenografts
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/onc.2014.219

Plant homeodomain finger 2 (PHF2) has a role in epigenetic regulation of gene expression by demethylating H3K9-Me2. Several genome-wide studies have demonstrated that the chromosomal region including the PHF2 gene is often deleted in some cancers including colorectal cancer, and this finding encouraged us to investigate the tumor suppressive role of PHF2. As p53 is a critical tumor suppressor in colon cancer, we tested the possibility that PHF2 is an epigenetic regulator of p53. PHF2 was associated with p53, and thereby, promoted p53-driven gene expression in cancer cells under genotoxic stress. PHF2 converted the chromatin that is favorable for transcription by demethylating the repressive H3K9-Me2 mark. In an HCT116 xenograft model, PHF2 was found to be required for the anticancer effects of oxaliplatin and doxorubicin. In PHF2-deficient xenografts, p53 expression was profoundly induced by both drugs, but its downstream product p21 was not, suggesting that p53 cannot be activated in the absence of PHF2. To find clinical evidence about the role of PHF2, we analyzed the expressions of PHF2, p53 and p21 in human colon cancer tissues and adjacent normal tissues from patients. PHF2 was downregulated in cancer tissues and PHF2 correlated with p21 in cancers expressing functional p53. Colon and stomach cancer tissue arrays showed a positive correlation between PHF2 and p21 expressions. Informatics analyses using the Oncomine database also supported our notion that PHF2 is downregulated in colon and stomach cancers. On the basis of these findings, we propose that PHF2 acts as a tumor suppressor in association with p53 in cancer development and ensures p53-mediated cell death in response to chemotherapy.